[{"address1": "930 Winter Street", "address2": "Suite M-500", "city": "Waltham", "state": "MA", "zip": "02451", "country": "United States", "phone": "617 443 2400", "website": "https://aerovatetx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts.", "fullTimeEmployees": 51, "companyOfficers": [{"maxAge": 1, "name": "Mr. Timothy P. Noyes M.B.A.", "age": 61, "title": "CEO & Director", "yearBorn": 1962, "fiscalYear": 2023, "totalPay": 936899, "exercisedValue": 0, "unexercisedValue": 10446414}, {"maxAge": 1, "name": "Mr. George A. Eldridge", "age": 60, "title": "CFO & Treasurer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 658600, "exercisedValue": 0, "unexercisedValue": 1968391}, {"maxAge": 1, "name": "Dr. Benjamin T. Dake Ph.D.", "age": 47, "title": "Founder, President, COO & Secretary", "yearBorn": 1976, "fiscalYear": 2023, "totalPay": 435500, "exercisedValue": 0, "unexercisedValue": 975487}], "auditRisk": 8, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1730073600, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.26, "open": 2.26, "dayLow": 2.19, "dayHigh": 2.27, "regularMarketPreviousClose": 2.26, "regularMarketOpen": 2.26, "regularMarketDayLow": 2.19, "regularMarketDayHigh": 2.27, "beta": 1.035, "forwardPE": -2.19, "volume": 52157, "regularMarketVolume": 52157, "averageVolume": 206165, "averageVolume10days": 109270, "averageDailyVolume10Day": 109270, "bid": 2.18, "ask": 2.21, "bidSize": 100, "askSize": 200, "marketCap": 64952336, "fiftyTwoWeekLow": 1.25, "fiftyTwoWeekHigh": 32.415, "fiftyDayAverage": 2.0241, "twoHundredDayAverage": 12.437, "currency": "USD", "enterpriseValue": -40300712, "floatShares": 11847020, "sharesOutstanding": 28867700, "sharesShort": 664994, "sharesShortPriorMonth": 1067065, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.023, "heldPercentInsiders": 0.00017999999, "heldPercentInstitutions": 1.00204, "shortRatio": 2.99, "shortPercentOfFloat": 0.0587, "impliedSharesOutstanding": 29658600, "bookValue": 3.271, "priceToBook": 0.6695201, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -87937000, "trailingEps": -3.13, "forwardEps": -1.0, "enterpriseToEbitda": 0.428, "52WeekChange": -0.80243576, "SandP52WeekChange": 0.3464489, "exchange": "NGM", "quoteType": "EQUITY", "symbol": "AVTE", "underlyingSymbol": "AVTE", "shortName": "Aerovate Therapeutics, Inc.", "longName": "Aerovate Therapeutics, Inc.", "firstTradeDateEpochUtc": 1625059800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "cbf275de-3fc7-3baa-b402-2df34de7643f", "messageBoardId": "finmb_650355034", "gmtOffSetMilliseconds": -14400000, "currentPrice": 2.19, "targetHighPrice": 3.0, "targetLowPrice": 2.0, "targetMeanPrice": 2.33, "targetMedianPrice": 2.0, "recommendationMean": 3.0, "recommendationKey": "hold", "numberOfAnalystOpinions": 3, "totalCash": 104202000, "totalCashPerShare": 3.61, "ebitda": -94108000, "totalDebt": 681000, "quickRatio": 6.122, "currentRatio": 6.508, "debtToEquity": 0.721, "returnOnAssets": -0.44035, "returnOnEquity": -0.74421, "freeCashflow": -44863624, "operatingCashflow": -74517000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-31"}]